Match Document Document Title
11367508 Systems and methods for detecting cellular pathway dysregulation in cancer specimens  
Disclosed herein are systems, methods, and compositions useful for determining cellular pathway disruption comprising the use of RNA expression level information. This determined level of...
11367004 Real-world evidence of diagnostic testing and treatment patterns in U.S. breast cancer patients with implications for treatment biomarkers from RNA-sequencing data  
Techniques are provided for replacing image assays using real world data and real word evidence RNA-seq analysis for assessing biologic pathways for identifying molecular subtypes. Systems of a...
11366117 Application of exosome TβRII protein as a marker in the preparation of breast cancer detection kit  
The present invention discloses an application of the exosome TβRII protein as a marker in preparing a breast cancer diagnostic kit, and belongs to the technology field of breast cancer detection...
11366100 P13K-MTORC1-S6K1 signaling pathway biomarkers predictive of anti-cancer responses  
The present invention is based, in part, on the identification of novel FI.3K-mTORCI-S6K 1 signaling pathway biomarkers predictive of responsiveness to anti-cancer therapies.
11365450 Group classification and prognosis prediction system based on biological characteristics of gastric cancer  
The present invention relates to a group classification and prognosis prediction system based on the biological characteristics of gastric cancer, and an algorithm capable of predicting the...
11365449 Kit or device for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions and detection method therefor  
This application provides a kit or a device for the detection of early pancreatic cancer or a pancreatic cancer precursor lesion, comprising a nucleic acid(s) capable of specifically binding to a...
11365415 Use of miR-223-3p as a cancer therapeutic and method for treating cancer using the same  
The subject invention provides a pharmaceutical composition comprising an inhibitory RNA (iRNA) that mediates sequence-specific degradation of the mRNA encoding Poly (ADP-ribose) polymerase 1...
11365259 IGF-1R antibody and its use as addressing vehicle for the treatment of cancer  
The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one...
11365250 Compositions and methods for cancer therapy  
The present disclosure generally relates to compositions and methods for cancer immunotherapy, as well as hematopoietic recovery following cancer treatment such as chemotherapy or irradiation.
11365227 Peptide and pharmaceutical compositions of same for use as an antimicrobial and in cancer treatment  
The present invention relates to a peptide derived from the defensin-3 from the red flour beetle Tribolium castaneum, to pharmaceutical compositions containing same, and to the use thereof as an...
11364291 Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer  
Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin...
11364264 Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer  
This disclosure is directed to methods of preparing dendritic cells or other CD40 bearing antigen-presenting cells and methods of treating cancer by using the dendritic cells or other...
11364243 Methods for treating cancer with a WEE1 inhibitor  
The present invention relates generally to the use of gene mutations, whose presence or absence are useful for predicting a patient's response to treatment with an anti-proliferative agent, in...
11364242 Treatment agents for inhibiting HIV and cancer in HIV infected patients  
Methods are provided for treating HIV and cancer in a subject in need thereof by administering to the subject therapeutically effective amounts of an mTOR inhibitor. Other methods are provided for...
11364237 Composition for inhibiting cancer metastasis and treating cancer  
The present invention relates to an anticancer and metastasis inhibiting effect by treatment with chlorphenesin, chloroquine, and chloropyrazine alone or in combination. Chlorphenesin,...
11364235 Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic  
This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting...
11364222 Combination therapy for treatment of cancer  
Compositions, combinations and methods comprising a CDK4/6 inhibitor of Formula D with a selective estrogen receptor downregulator of Formula A, B or C that are advantageous for the treatment of...
11364210 Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria and pathogenic yeast  
The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial...
11361841 High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies  
Systems and methods are presented that allow for selection of tumor neoepitopes that are filtered for various criteria. In particularly contemplated aspects, filtering includes a step in which the...
11360093 Colorectal cancer diagnostic composition, and method for detecting diagnostic marker  
The present invention relates to a colorectal cancer diagnostic composition and method for detecting a diagnostic marker, more specifically to a colorectal cancer diagnostic composition comprising...
11360092 Keratin 17 as a biomarker for bladder cancer  
The current disclosure provides methods for detecting and analyzing K17 expression in a bladder sample obtained from a subject. The current disclosure also pertains to methods and kits for...
11359200 Cancer treatment by MALAT1 inhibition  
Compositions and methods for treating cancer in a subject in need thereof are described that includes administering a therapeutically effective amount of an oligonucleotide that specifically...
11359013 Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway  
The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and...
11359003 Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers  
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The...
11357862 Peptide-conjugated nanoparticles for targeting, imaging, and treatment of prostate cancer  
An isolated or a synthetic targeting peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 8 is disclosed. The targeting peptide may be conjugated to a component...
11357850 Methods for treating breast cancer using INOS-inhibitory compositions  
Disclosed are methods for treating one or more mammalian cancers, particularly, human breast cancers, including triple-negative breast cancer (TNBC), that employ therapeutically-effective amounts...
11357842 PD-L1 targeting DNA vaccine for cancer immunotherapy  
The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding PD-L1. In particular, the present...
11357840 Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors  
The described invention relates to a pharmaceutical composition comprising a therapeutically effect amount of a therapeutic agent, wherein the therapeutic agent is effective (1) to reduce tumor...
11357795 Combination immunotherapies for treatment of cancer  
Described herein are compositions and methods for treating a disease, particularly a cancer, with an immune checkpoint modulatory agent and a strain of an Arbovirus or a strain of an Alphavirus....
11357766 Compositions and methods for treating cancer  
The present invention includes composition and methods for treating cancers comprising administering to a subject a pharmaceutical composition comprising Pimavanserin or derivatives thereof in an...
11357742 Methods for treating cancer  
The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic...
11353459 Methods of using PD-L1 expression in treatment decisions for cancer therapy  
Methods of using detection of PD-L1 expression by circulating cancer cells in the screening, monitoring, treatment and diagnosis of cancer in subjects are disclosed. The methods are based on...
11352673 Method for the diagnosis, prognosis and treatment of lung cancer metastasis  
The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample....
11352672 Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor  
The present disclosure provides methods and reagents for the diagnosis, prognosis or the monitoring of breast cancer, including various subtypes of breast cancer including, for example, estrogen...
11352627 Treatment of HER-2 dependent cancer using an agent that modulates the activity of a miRNA  
This invention relates to an agent that modulates the activity of a micro ribonucleic acid (miRNA), said miRNA being selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29b-3p,...
11352430 Humanized anti-human-PD-1 antibody and its use in cancer treatment  
Described herein are humanized anti-PD-1 antibodies, nucleic acids encoding such, and uses thereof in enhancing immune responses by activating T cells and treating diseases such as cancer and an...
11352401 Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers  
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The...
11352387 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds  
Disclosed are chemical compounds, the compounds for use in a method of treatment, particularly in a method of prophylaxis or treatment for cancer, a process for preparation of the compounds and...
11351255 Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant  
The present document describes a method of inhibiting cancer tumor growth in a patient in need thereof, comprising at least a first treatment comprising steps a) and b): a) administering to the...
11351254 Hematologic cancer treatments  
Disclosed herein are improved compositions and methods involved in treating hematologic cancers, i.e., cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the...
11351250 Pro-inflammatory and anti-cancer functions of toll-like receptor 4 antagonists  
The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC)...
11351237 CMV-based intra-tumoral cancer therapies  
A CMV-based vaccine that promotes immune-mediated destruction of cancer through a onetime or repeated intratumoral administration of a recombinant CMV to generate a robust, long-lasting anti-tumor...
11351209 Inhibitors of PI3K p-delta 110 for use in delivery of viruses in the treatment of cancer  
The present invention provides a composition comprising a phosphatidylinositol 3-kinase (PI3K) inhibitor and a modified virus for separate, subsequent or simultaneous use in the treatment of...
11351185 Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis  
A pharmaceutical composition containing any one or more of 4″-O-isolvalerylspiramycin I, II and III counters tumorigenesis and reduces or prevents metastasis by inhibiting selenoprotein H to...
11351165 Agent that increases the expression of the opioid kappa 1 for the treatment of cancer  
It has been found by the present inventors that agents that boost the expression of the opioid receptor kappa 1 (OPRK1) can enhance the cytotoxicity of chemotherapeutic agents in multiple cancer...
11351163 Compositions and methods of treating cancer  
The disclosure is directed to methods of treating cancer in subjects with a combination of a monoclonal antibody and (R)-N-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4-yl)cyclo hexyl)propanamide,...
11351160 Methods of treating cancer  
The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops...
11351156 Combination treatment of pancreatic cancer  
PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling....
11350992 Neuromodulation and associated systems and methods for the treatment of cancer  
Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several...
11350901 Recurrence prognosis and prediction of added benefit of adjuvant chemotherapy in early stage non-small cell lung cancer with radiomic features on baseline computed tomography  
Embodiments generate an early stage NSCLC recurrence prognosis, and predict added benefit of adjuvant chemotherapy. Embodiments include processors configured to access a radiological image of a...